Filing Details

Accession Number:
0000899243-23-015998
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-20 17:23:01
Reporting Period:
2023-06-15
Accepted Time:
2023-06-20 17:23:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590750 Viridian Therapeutics Inc. VRDN Services-Medical Laboratories (8071) 471187261
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1883986 Lara Meisner C/O Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham MA 02453
Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-15 2,269 $23.03 32,240 No 4 M Direct
Common Stock Disposition 2023-06-15 2,269 $28.02 29,971 No 4 S Direct
Common Stock Acquisiton 2023-06-16 27 $23.03 29,998 No 4 M Direct
Common Stock Disposition 2023-06-16 27 $28.35 29,971 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-06-15 2,269 $0.00 2,269 $23.03
Common Stock Stock Option (Right to Buy) Disposition 2023-06-16 28 $0.00 28 $23.03
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
37,481 2031-01-18 No 4 M Direct
37,453 2031-01-18 No 4 M Direct
Footnotes
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. This transaction was executed pursuant to the Plan.
  3. The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.